CELLDEX THERAPEUTICS INC NEW's ticker is CLDX and the CUSIP is 15117B202. A total of 161 filers reported holding CELLDEX THERAPEUTICS INC NEW in Q1 2023. The put-call ratio across all filers is 0.51 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $544,896 | -64.0% | 19,800 | -52.9% | 0.01% | -58.1% |
| Q1 2023 | $1,513,894 | +8.6% | 42,076 | +34.5% | 0.03% | -3.1% |
| Q4 2022 | $1,393,838 | +33.6% | 31,273 | -15.7% | 0.03% | +23.1% |
| Q3 2022 | $1,043,000 | -82.9% | 37,118 | -83.6% | 0.03% | -83.8% |
| Q2 2022 | $6,086,000 | +7.6% | 225,765 | +35.9% | 0.16% | +22.1% |
| Q1 2022 | $5,657,000 | -4.3% | 166,065 | +8.6% | 0.13% | -5.8% |
| Q4 2021 | $5,910,000 | -30.9% | 152,950 | -3.4% | 0.14% | -41.1% |
| Q3 2021 | $8,547,000 | +112.6% | 158,309 | +31.7% | 0.24% | +82.9% |
| Q2 2021 | $4,021,000 | +163.2% | 120,238 | +62.0% | 0.13% | +126.3% |
| Q1 2021 | $1,528,000 | -51.5% | 74,199 | -58.7% | 0.06% | -51.3% |
| Q4 2020 | $3,148,000 | +14.1% | 179,670 | -3.5% | 0.12% | -29.9% |
| Q3 2020 | $2,760,000 | +1.7% | 186,117 | -10.9% | 0.17% | -10.2% |
| Q2 2020 | $2,715,000 | – | 208,836 | – | 0.19% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Kynam Capital Management, LP | 3,200,000 | $88,064,000 | 14.40% |
| Octagon Capital Advisors LP | 759,898 | $20,912,393 | 3.21% |
| TSP Capital Management Group, LLC | 251,695 | $6,926,645 | 2.67% |
| 5AM Venture Management, LLC | 310,270 | $8,538,630 | 2.46% |
| COMMODORE CAPITAL LP | 706,665 | $19,447,421 | 2.27% |
| ACUTA CAPITAL PARTNERS, LLC | 122,341 | $3,366,824 | 2.26% |
| Redmile Group, LLC | 1,635,938 | $45,021,014 | 2.14% |
| RTW INVESTMENTS, LP | 3,463,201 | $95,307,292 | 2.01% |
| Eversept Partners, LP | 588,143 | $16,185,695 | 1.37% |
| Affinity Asset Advisors, LLC | 150,000 | $4,128,000 | 1.16% |